open access

Vol 73, No 6 (2022)
Original paper
Submitted: 2022-05-02
Accepted: 2022-06-06
Published online: 2022-09-05
Get Citation

Is multifocality a risk factor in low-risk papillary thyroid cancer?

Giulia Sapuppo12, Sonia Grasso1, Guenda Di Benedetto1, Ilenia Marturano3, Gabriele Costanzo1, Antonino Belfiore1, Gabriella Pellegriti3
·
Pubmed: 36094871
·
Endokrynol Pol 2022;73(6):928-934.
Affiliations
  1. Endocrinology, Department of Clinical and Molecular Biomedicine, Garibaldi-Nesima Medical Center, University of Catania, Italy
  2. Centre of Experimental Oncology and Haematology, Department of Clinical and Experimental Medicine, Policlinico “G. Rodolico-San Marco” Medical Centre, Catania, Italy
  3. Endocrinology, Garibaldi-Nesima Medical Centre, Catania, Italy

open access

Vol 73, No 6 (2022)
Original Paper
Submitted: 2022-05-02
Accepted: 2022-06-06
Published online: 2022-09-05

Abstract

Introduction: Multifocality in papillary thyroid cancer (PTC) is a common event, ranging from 18% to 87%. Additional multiple foci are frequently very small and generally detected in pathology specimens. The mechanisms of intrathyroidal spread, and its correlation with age, gender, tumour size, and lymph node metastases remain unclear. Moreover, studies assessing the prognostic impact of PTC multifocality have yielded non-univocal results. We aimed to evaluate the following: a) the histopathological and clinical characteristics associated with multifocal PTC; and b) the impact of multifocality on the long-term outcome.

Material and methods: We analysed a consecutive series of 2814 PTC patients without evidence of microscopic extrathyroidal extension (T1a, T1b, and T2), all of whom had undergone total thyroidectomy and were followed-up (median 4.7 years) in our thyroid clinic. Females comprised 81.3% and males 18.7% (F/M = 4.4/1), with a median age at diagnosis of 45.0 years. Patients were subdivided into 2 groups: 72.7% unifocal tumour and 27.3% multifocal tumour. Post-surgical radioiodine ablation (RAI) (30–100 mCi of 131-I) was performed in 1425 (50.6%) patients. All patients were periodically followed with thyroglobulin and anti-thyroglobulin antibodies measurements and with neck ultrasonography under L-thyroxine therapy and subjected to additional radioiodine administration or another therapeutic measure
if not cured.

Results: Patients in the multifocal group were older (median age 46.4 vs. 44.5 years, respectively, p < 0.05) and presented a lower F/M ratio (F/M = 3.7/1 and 4.7/1; p = 0.01). T1a and T1b tumours showed no significant difference in multifocality rate whereas T2 tumours were less frequently multifocal (14.2% vs. 10.9%, p < 0.05). Multifocal tumours were more frequent in N1b (11.3% vs. 7.8%, p < 0.01) and less frequent in Nx (50.5% vs. 56.8%, p < 0.01), with no difference between the N0 and N1a groups. The clinical outcome was similar in the 2 group of patients (88.2 % in the unifocal group vs. 90.2% in the multifocal group).

Conclusions: Multifocality is more frequent in older and male patients, in smaller tumours, and in N1b. However, multifocality “per se” was not associated, in our study, with worse clinical outcome in PTC patients.

Abstract

Introduction: Multifocality in papillary thyroid cancer (PTC) is a common event, ranging from 18% to 87%. Additional multiple foci are frequently very small and generally detected in pathology specimens. The mechanisms of intrathyroidal spread, and its correlation with age, gender, tumour size, and lymph node metastases remain unclear. Moreover, studies assessing the prognostic impact of PTC multifocality have yielded non-univocal results. We aimed to evaluate the following: a) the histopathological and clinical characteristics associated with multifocal PTC; and b) the impact of multifocality on the long-term outcome.

Material and methods: We analysed a consecutive series of 2814 PTC patients without evidence of microscopic extrathyroidal extension (T1a, T1b, and T2), all of whom had undergone total thyroidectomy and were followed-up (median 4.7 years) in our thyroid clinic. Females comprised 81.3% and males 18.7% (F/M = 4.4/1), with a median age at diagnosis of 45.0 years. Patients were subdivided into 2 groups: 72.7% unifocal tumour and 27.3% multifocal tumour. Post-surgical radioiodine ablation (RAI) (30–100 mCi of 131-I) was performed in 1425 (50.6%) patients. All patients were periodically followed with thyroglobulin and anti-thyroglobulin antibodies measurements and with neck ultrasonography under L-thyroxine therapy and subjected to additional radioiodine administration or another therapeutic measure
if not cured.

Results: Patients in the multifocal group were older (median age 46.4 vs. 44.5 years, respectively, p < 0.05) and presented a lower F/M ratio (F/M = 3.7/1 and 4.7/1; p = 0.01). T1a and T1b tumours showed no significant difference in multifocality rate whereas T2 tumours were less frequently multifocal (14.2% vs. 10.9%, p < 0.05). Multifocal tumours were more frequent in N1b (11.3% vs. 7.8%, p < 0.01) and less frequent in Nx (50.5% vs. 56.8%, p < 0.01), with no difference between the N0 and N1a groups. The clinical outcome was similar in the 2 group of patients (88.2 % in the unifocal group vs. 90.2% in the multifocal group).

Conclusions: Multifocality is more frequent in older and male patients, in smaller tumours, and in N1b. However, multifocality “per se” was not associated, in our study, with worse clinical outcome in PTC patients.

Get Citation

Keywords

papillary thyroid cancer; multifocality; multifocal tumour; thyroid cancer outcome; risk factors

About this article
Title

Is multifocality a risk factor in low-risk papillary thyroid cancer?

Journal

Endokrynologia Polska

Issue

Vol 73, No 6 (2022)

Article type

Original paper

Pages

928-934

Published online

2022-09-05

Page views

3747

Article views/downloads

391

DOI

10.5603/EP.a2022.0073

Pubmed

36094871

Bibliographic record

Endokrynol Pol 2022;73(6):928-934.

Keywords

papillary thyroid cancer
multifocality
multifocal tumour
thyroid cancer outcome
risk factors

Authors

Giulia Sapuppo
Sonia Grasso
Guenda Di Benedetto
Ilenia Marturano
Gabriele Costanzo
Antonino Belfiore
Gabriella Pellegriti

References (51)
  1. Shin HR, Masuyer E, Ferlay J, et al. Asian Contributors to CI. Cancer in Asia — Incidence rates based on data in cancer incidence in five continents IX (1998–2002). Asian Pac J Cancer Prev. 2010; 11(Suppl 2): 11–6.
  2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014; 140(4): 317–322.
  3. Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017; 317(13): 1338–1348.
  4. Chow SM, Law SCK, Chan JKC, et al. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003; 98(1): 31–40.
  5. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996; 5(1): 43–63.
  6. Hay I, Hutchinson M, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period. Surgery. 2008; 144(6): 980–988.
  7. American Cancer Society. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf..
  8. Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2017; 123(3): 372–381.
  9. Nakazawa T, Kondo T, Tahara I, et al. Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis. Cancer Med. 2015; 4(8): 1272–1280.
  10. Lu Z, Sheng J, Zhang Y, et al. Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. J Pathol. 2016; 239(1): 72–83.
  11. Sargent D. General and statistical hierarchy of appropriate biologic endpoints. Oncology (Williston Park). 2006; 20(6 Suppl 5): 5–9.
  12. DeLellis RA, Lloyd RV, Heitz PU, Eng V. (eds). Pathology and Genetics of Tumours of Endocrine Organs. 4th ed. IARC Press, Lyon 2004.
  13. Joseph KR, Edirimanne S, Eslick GD. Multifocality as a prognostic factor in thyroid cancer: A meta-analysis. Int J Surg. 2018; 50: 121–125.
  14. Ardito G, Revelli L, Giustozzi E, et al. Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med. 2013; 38(1): 25–28.
  15. Sapuppo G, Tavarelli M, Belfiore A, et al. Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes. J Clin Endocrinol Metab. 2019; 104(2): 258–265.
  16. Sapuppo G, Palermo F, Russo M, et al. Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome. J Endocrinol Invest. 2017; 40(12): 1355–1363.
  17. Guo K, Wang Z. Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2014; 7(9): 5393–5403.
  18. Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients. Ann Surg Oncol. 2015; 22(1): 125–131.
  19. Tam AA, Özdemir D, Çuhacı N, et al. Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer. Endocrine. 2016; 53(3): 774–783.
  20. Muzza M. The clonal origin of multifocal papillary thyroid cancer: intrathyroidal spread or independent tumors? Minerva Endocrinol (Torino). 2021; 46(1): 35–44.
  21. Muzza M, Pogliaghi G, Persani L, et al. Combined Mutational and Clonality Analyses Support the Existence of Intra-Tumor Heterogeneity in Papillary Thyroid Cancer. J Clin Med. 2021; 10(12).
  22. Cooper DS, Doherty GM, Haugen BR, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11): 1167–1214.
  23. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007; 13(5): 498–512.
  24. Roti E, degli Uberti EC, Bondanelli M, et al. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008; 159(6): 659–673.
  25. Geron Y, Benbassat C, Shteinshneider M, et al. Multifocality Is not an Independent Prognostic Factor in Papillary Thyroid Cancer: A Propensity Score-Matching Analysis. Thyroid. 2019; 29(4): 513–522.
  26. Zhang T, He L, Wang Z, et al. The Differences Between Multifocal and Unifocal Papillary Thyroid Carcinoma in Unilateral Lobe: A Meta-Analysis. Front Oncol. 2021; 11: 657237.
  27. Buffet C, Golmard JL, Hoang C, et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol. 2012; 167(2): 267–275.
  28. Besic N, Pilko G, Petric R, et al. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol. 2008; 97(3): 221–225.
  29. Ahn JY, Lee MiJ, Kim H, et al. Epidemiological and Survival Trends of Pediatric Cardiac Arrests in Emergency Departments in Korea: A Cross-sectional, Nationwide Report. J Korean Med Sci. 2015; 30(9): 1354–1360.
  30. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008; 144(6): 980–7; discussion 987.
  31. Choi WRi, Roh JL, Gong G, et al. Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence. Oral Oncol. 2019; 94: 106–110.
  32. Ywata de Carvalho A, Kohler HF, Gomes CC, et al. Predictive factors for recurrence of papillary thyroid carcinoma: analysis of 4,085 patients. Acta Otorhinolaryngol Ital. 2021; 41(3): 236–242.
  33. Kim H, Kwon H, Moon BI. Association of Multifocality With Prognosis of Papillary Thyroid Carcinoma: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021; 147(10): 847–854.
  34. Wang F, Yu X, Shen X, et al. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2017; 102(9): 3241–3250.
  35. Mendelsohn AH, Elashoff DA, Abemayor E, et al. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010; 136(11): 1055–1061.
  36. Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012; 151(4): 571–579.
  37. Shah JP, Loree TR, Dharker D, et al. Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis. Am J Surg. 1993; 166(4): 331–335.
  38. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001; 86(4): 1447–1463.
  39. Hay I, Grant C, Bergstralh E, et al. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998; 124(6): 958–966.
  40. Hirokawa M, Maekawa M, Kuma S, et al. Cribriform-morular variant of papillary thyroid carcinoma--cytological and immunocytochemical findings of 18 cases. Diagn Cytopathol. 2010; 38(12): 890–896.
  41. Ito Y, Miyauchi A, Ishikawa H, et al. Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients. Endocr J. 2011; 58(8): 685–689.
  42. Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014; 38(1): 68–79.
  43. Vaisman F, Shaha A, Fish S, et al. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011; 75(1): 112–119.
  44. Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. 2011; 150(6): 1048–1057.
  45. Sancho JJ, Lennard TW, Paunovic I, et al. Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014; 399(2): 155–163.
  46. Sywak M, Cornford L, Roach P, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006; 140(6): 1000–5; discussion 1005.
  47. Al Afif A, Williams BA, Rigby MH, et al. Multifocal Papillary Thyroid Cancer Increases the Risk of Central Lymph Node Metastasis. Thyroid. 2015; 25(9): 1008–1012.
  48. Ross DS, Litofsky D, Ain KB, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009; 19(10): 1043–1048.
  49. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998; 83(3): 553–559, doi: 10.1002/(sici)1097-0142(19980801)83:3<553::aid-cncr25>3.0.co;2-u.
  50. Kim HJ, Kim NaK, Choi JiH, et al. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2013; 78(4): 614–620.
  51. Manso J, Censi S, Roberti A, et al. Prognostic significance of the sum of the diameters of single foci in multifocal papillary thyroid cancer: the concept of new-old tumor burden. Ther Adv Endocrinol Metab. 2020; 11: 2042018820964326.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl